Edition:
United States

Corbus Pharmaceuticals Holdings Inc (CRBP.OQ)

CRBP.OQ on NASDAQ Stock Exchange Global Market

6.95USD
21 Sep 2018
Change (% chg)

$-1.00 (-12.58%)
Prev Close
$7.95
Open
$7.30
Day's High
$7.30
Day's Low
$6.38
Volume
1,860,786
Avg. Vol
127,810
52-wk High
$9.85
52-wk Low
$4.53

Latest Key Developments (Source: Significant Developments)

Corbus Pharmaceuticals Says Co Obligated To Pay Jenrin Potential Milestone Payments Of Up To $18.4 Mln For Each Compound Elects To Develop
Thursday, 20 Sep 2018 08:53am EDT 

Sept 20 (Reuters) - Corbus Pharmaceuticals Holdings Inc ::CORBUS PHARMACEUTICALS- CO OBLIGATED TO PAY JENRIN POTENTIAL MILESTONE PAYMENTS OF UP TO $18.4 MILLION FOR EACH COMPOUND ELECTS TO DEVELOP.CORBUS PHARMACEUTICALS SAYS CO OBLIGATED TO PAY JENRIN ROYALTIES IN MID, SINGLE DIGITS BASED ON NET SALES OF ANY LICENSED PRODUCTS - SEC FILING.CORBUS PHARMACEUTICALS-FOR 10 YRS FROM DEAL, JENRIN/AFFILIATES WILL NOT DEVELOP/COMMERCIALIZE COMPOUNDS INTENDED TO/DO, MODULATE CANNABINOID RECEPTOR.  Full Article

Corbus Pharmaceuticals Expands Target Indications By Adding Over 600 Compounds Focused On Endocannabinoid System From Jenrin Discovery
Thursday, 20 Sep 2018 07:19am EDT 

Sept 20 (Reuters) - Corbus Pharmaceuticals Holdings ::CORBUS PHARMACEUTICALS EXPANDS TARGET INDICATIONS BY ADDING OVER 600 COMPOUNDS FOCUSED ON ENDOCANNABINOID SYSTEM FROM JENRIN DISCOVERY LLC.CORBUS PHARMACEUTICALS SAYS TRANSACTION EXPECTED TO HAVE MINIMAL IMPACT ON CO'S CASH FLOW THROUGH END OF 2019.CORBUS PHARMACEUTICALS SAYS PIPELINE INCLUDES CRB-4001, A NOVEL CB-1 INVERSE AGONIST, SCHEDULED BY CO TO ENTER PHASE 1 STUDY IN 2019.CORBUS PHARMACEUTICALS SAYS DEAL FOR UP-FRONT CASH PAYMENT, MILESTONE PAYMENTS TO BE PAID ON ACHIEVEMENT OF SOME DEVELOPMENT & REGULATORY MILESTONES.CORBUS PHARMACEUTICALS - BELIEVES PIPELINE WILL SUPPORT ADVANCEMENT OF 1 TO 2 NEW DRUG CANDIDATES INTO CLINICAL TESTING EACH YEAR STARTING 2020.CORBUS PHARMACEUTICALS SAYS A PHASE 3 STUDY OF LENABASUM FOR TREATMENT OF DERMATOMYOSITIS PLANNED TO BEGIN END OF 2018.  Full Article

Corbus Pharmaceuticals Reports 2017 Financial Results And Provides Clinical Update
Monday, 12 Mar 2018 07:05am EDT 

March 12 (Reuters) - Corbus Pharmaceuticals Holdings Inc ::CORBUS PHARMACEUTICALS REPORTS 2017 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATE.CORBUS PHARMACEUTICALS HOLDINGS INC - CASH AND CASH EQUIVALENTS BALANCE AT DECEMBER 31, 2017 WAS APPROXIMATELY $62.5 MILLION.CORBUS PHARMACEUTICALS - EXPECTS CURRENT CASH ON HAND, EXPECTED MILESTONE PAYMENTS TO FUND OPERATIONS THROUGH Q4 OF 2019.  Full Article

Corbus Pharmaceuticals Files For Mixed Shelf Of Up To $200 Mln ‍​
Friday, 5 Jan 2018 05:10pm EST 

Jan 5 (Reuters) - Corbus Pharmaceuticals Holdings Inc ::CORBUS PHARMACEUTICALS HOLDINGS INC FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILING ‍​.  Full Article

Corbus Pharmaceuticals Q3 loss per share $0.14
Wednesday, 8 Nov 2017 08:05am EST 

Nov 8 (Reuters) - Corbus Pharmaceuticals Holdings Inc : :Corbus Pharmaceuticals reports 2017 third quarter financial results and highlights recent corporate and clinical advancements.Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.Q3 loss per share $0.14.Corbus Pharmaceuticals Holdings Inc - ‍company expects current cash on hand to fund operations into Q4 of 2019,based on current planned expenditures​.Corbus Pharmaceuticals Holdings Inc - qtrly revenue $796,312 versus $742,558.  Full Article

Corbus Pharma reports improvement in skin conditions in a mid-stage study
Monday, 6 Nov 2017 08:30am EST 

Nov 6 (Reuters) - Corbus Pharmaceuticals Holdings Inc :Corbus Pharmaceuticals reports significant improvement in mRSS and other clinical outcomes at 28-weeks in systemic sclerosis open-label extension of phase 2 study.Corbus Pharmaceuticals Holdings Inc - ‍Company on track to commence phase 3 study Q4 2017​.Corbus Pharmaceuticals Holdings Inc - Were no severe or serious adverse events and no clinically significant laboratory abnormalities related to drug​.Corbus Pharmaceuticals - "‍Our focus now is to ensure successful execution of our phase 3 study, and we are on track to commence this before year end"​.  Full Article

Corbus Pharma prices underwritten public offering of common stock
Tuesday, 24 Oct 2017 09:06am EDT 

Oct 24 (Reuters) - Corbus Pharmaceuticals Holdings Inc :Corbus Pharmaceuticals Holdings, Inc. prices underwritten public offering of common stock.Says public offering of 4.65 million common shares priced at $7.00 per share.  Full Article

Corbus Pharmaceuticals Holdings announces proposed public offering of common stock
Monday, 23 Oct 2017 04:01pm EDT 

Oct 24 (Reuters) - Corbus Pharmaceuticals Holdings Inc :Corbus Pharmaceuticals Holdings Inc announces proposed public offering of common stock.Corbus Pharmaceuticals Holdings Inc - ‍Corbus intends to use proceeds of proposed offering to fund its continued development of anabasum, among others​.  Full Article

Corbus Pharma's inflammatory disease drug succeeds mid-stage study
Thursday, 19 Oct 2017 07:30am EDT 

Oct 19 (Reuters) - Corbus Pharmaceuticals Holdings Inc :Corbus Pharmaceuticals reports positive topline results from phase 2 study in rare autoimmune disease dermatomyositis.Corbus Pharmaceuticals Holdings Inc - ‍Anabasum was well tolerated with no severe or serious side effects associated with drug​.Corbus Pharmaceuticals Holdings Inc - ‍Anabasum also outperformed placebo in multiple secondary efficacy outcomes studied​.  Full Article

Corbus Pharmaceuticals Holdings reports Q2 loss per share $0.15
Wednesday, 9 Aug 2017 07:05am EDT 

Aug 9 (Reuters) - Corbus Pharmaceuticals Holdings Inc :Corbus Pharmaceuticals reports 2017 second quarter financial results and provides business update.Q2 loss per share $0.15.Q2 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S.Corbus Pharmaceuticals Holdings Inc - ‍ended Q2 with approximately $43.0 million of cash and cash equivalents​.  Full Article

BRIEF-Corbus Pharmaceuticals Reports Q1 Loss Per Share $0.21

* CORBUS PHARMACEUTICALS REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE